#1 Clinical Trials Search in Europe

Temocillin Sodium

This article summarizes several clinical trials investigating the use of temocillin sodium, an antibiotic, for treating various bacterial infections. The trials examine temocillin’s efficacy, safety, and pharmacokinetics in different patient populations and infection types, with a focus on its potential as an alternative to carbapenems for treating resistant bacteria.

Table of Contents

What is Temocillin?

Temocillin sodium, also known by its brand name Negaban, is an antibiotic medication that belongs to the penicillin family[1]. It was first developed in the 1980s but was largely abandoned until recent years when it gained renewed interest due to its effectiveness against certain types of antibiotic-resistant bacteria[1].

Temocillin is unique because it has a special chemical structure that makes it resistant to many enzymes (called beta-lactamases) that bacteria produce to defend themselves against antibiotics. This resistance to beta-lactamases gives temocillin an advantage in treating infections caused by bacteria that have become resistant to other antibiotics[1].

What Does Temocillin Treat?

Temocillin is approved for treating various bacterial infections, including:

  • Urinary tract infections (UTIs): Including complicated UTIs and kidney infections (pyelonephritis)[2]
  • Respiratory tract infections: Such as lung infections[1]
  • Bloodstream infections: Also known as bacteremia[1]
  • Abdominal infections[1]
  • Wound infections[1]

Temocillin is particularly useful for treating infections caused by bacteria that produce extended-spectrum beta-lactamases (ESBLs). These are enzymes that make bacteria resistant to many common antibiotics. Temocillin remains effective against many ESBL-producing bacteria, making it a valuable treatment option when other antibiotics fail[2].

How Does Temocillin Work?

Temocillin works by interfering with the way bacteria build their cell walls. Without proper cell walls, bacteria cannot survive. Specifically, temocillin targets and kills Gram-negative bacteria, which are a type of bacteria that have a thin cell wall. This group includes many common causes of infections, such as E. coli and Klebsiella[3].

What makes temocillin special is its ability to resist breakdown by beta-lactamase enzymes produced by some bacteria. This resistance allows temocillin to remain effective against certain antibiotic-resistant bacteria, making it a valuable “sparing” drug for more powerful antibiotics like carbapenems[4].

How is Temocillin Administered?

Temocillin is typically given as an intravenous (IV) infusion in a hospital setting. The usual adult dose is 2 grams given every 12 hours, but this can vary depending on the type and severity of the infection[1]. Some key points about temocillin administration include:

  • It’s usually given as an infusion over 30-40 minutes[4]
  • In some cases, it may be given as a continuous infusion over 24 hours[4]
  • The dose and frequency may need to be adjusted for patients with kidney problems[3]
  • Treatment duration typically ranges from 7 to 14 days, depending on the type and severity of the infection[5]

Effectiveness of Temocillin

Several studies have shown temocillin to be effective in treating various infections, particularly those caused by ESBL-producing bacteria. For example:

  • In urinary tract infections caused by ESBL-producing bacteria, temocillin has shown promising results[2]
  • It has been effective in treating bloodstream infections (bacteremia) caused by antibiotic-resistant bacteria[5]
  • Temocillin has shown potential as an alternative to more broad-spectrum antibiotics like carbapenems, which could help reduce the development of antibiotic resistance[4]

Temocillin in Special Populations

Research is ongoing to understand how temocillin can be used in different patient groups:

  • Patients on hemodialysis: Studies are investigating the best dosing schedules for patients with kidney failure who are on dialysis[3]
  • Children: Research is being conducted to determine the appropriate dosing and effectiveness of temocillin in pediatric patients[6]
  • Intensive Care Unit (ICU) patients: Studies are exploring the use of temocillin in critically ill patients with severe infections[7]

Possible Side Effects

Like all medications, temocillin can cause side effects. Some potential side effects include:

  • Diarrhea
  • Pain at the injection site
  • Skin rash
  • Fever
  • Joint or muscle pain

In rare cases, more serious side effects like severe allergic reactions (anaphylaxis) or neurological disorders may occur, especially in patients with kidney problems[1]. Always inform your healthcare provider of any side effects you experience.

Ongoing Research

Several clinical trials are currently underway to further investigate the use of temocillin:

  • Comparing temocillin to carbapenems for treating urinary tract infections caused by ESBL-producing bacteria[4]
  • Evaluating temocillin as an alternative to carbapenems for treating bloodstream infections[5]
  • Investigating the impact of temocillin on gut bacteria compared to other antibiotics[8]
  • Studying the use of temocillin in combination with other antibiotics for severe infections in ICU patients[7]

These ongoing studies aim to provide more information about the effectiveness and safety of temocillin in various clinical situations, potentially expanding its use and helping to combat antibiotic resistance.

Aspect Details
Main Indications Urinary tract infections, bacteremia, infections due to ESBL-producing Enterobacteriaceae
Patient Populations Adults, children, patients on hemodialysis, critically ill patients
Dosing Regimens Varies by study: 2g every 8 hours, 6g/day continuous infusion, adjusted for renal function
Comparator Drugs Carbapenems (meropenem, imipenem), cefotaxime
Primary Outcomes Clinical cure, microbiological eradication, pharmacokinetic parameters
Safety Considerations Monitoring for adverse events, C. difficile infection, development of resistance
Special Populations Studies in pediatrics, hemodialysis patients, critically ill patients

FAQ

  • What is temocillin sodium? Temocillin sodium is an antibiotic that belongs to the penicillin class. It is effective against many Gram-negative bacteria, including those that produce extended-spectrum beta-lactamases (ESBLs), making it a potential alternative to carbapenems for treating resistant infections.
  • What types of infections is temocillin being studied for? Clinical trials are investigating temocillin for treating urinary tract infections, bloodstream infections, and other severe infections caused by ESBL-producing and AmpC hyperproducing Enterobacteriaceae. It is also being studied in patients with kidney failure requiring hemodialysis.
  • How is temocillin administered? Temocillin is typically administered intravenously. The dosage and frequency can vary depending on the specific infection and patient characteristics. Some trials are studying different dosing regimens, such as 2g every 8 hours or 6g per day as a continuous infusion.
  • What are the potential advantages of using temocillin over other antibiotics? Temocillin may offer an alternative to carbapenems for treating resistant infections, potentially helping to reduce carbapenem use and slow the development of carbapenem resistance. It has a narrow spectrum of activity, which may lead to less disruption of the normal gut microbiota compared to broader-spectrum antibiotics.
  • Are there any special considerations for using temocillin in patients with kidney problems? Yes, temocillin dosing may need to be adjusted in patients with kidney impairment. Some trials are specifically studying the pharmacokinetics and appropriate dosing of temocillin in patients undergoing hemodialysis to ensure safe and effective use in this population.

Ongoing Clinical Trials on Temocillin Sodium

  • Study on Piperacillin-Tazobactam and Temocillin for Treating Severe Infections in ICU Patients with ESBL-Producing Gram-Negative Bacteria

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Temocillin Compared with Ceftriaxone for Gonorrhea Infection in Adults

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of Temocillin and Meropenem for Patients with Infections Caused by Resistant Enterobacteriaceae

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Extended-spectrum beta-lactamases (ESBLs): Enzymes produced by some bacteria that can break down and inactivate certain antibiotics, making the bacteria resistant to those drugs.
  • Carbapenem: A class of powerful antibiotics used to treat serious infections, often reserved as a last line of defense against resistant bacteria.
  • Enterobacteriaceae: A large family of Gram-negative bacteria that includes many common pathogens such as E. coli and Klebsiella species.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • AmpC beta-lactamases: Enzymes produced by some bacteria that can provide resistance to certain antibiotics, including some cephalosporins.
  • Gram-negative bacteria: A class of bacteria that do not retain crystal violet dye in the Gram staining protocol, often having a different cell wall structure compared to Gram-positive bacteria.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Pyelonephritis: A type of urinary tract infection that affects one or both kidneys.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ dysfunction.

References

  1. https://clinicaltrials.gov/study/NCT03557840
  2. https://clinicaltrials.gov/study/NCT02681263
  3. https://clinicaltrials.gov/study/NCT02285075
  4. https://clinicaltrials.gov/study/NCT03543436
  5. https://clinicaltrials.eu/trial/56672/
  6. https://clinicaltrials.gov/study/NCT02260102
  7. https://clinicaltrials.gov/study/NCT05565222
  8. https://clinicaltrials.gov/study/NCT02959957